Ozempic / GLP-1

What the Ozempic / GLP-1 lawsuit is about

Ozempic and other GLP-1 lawsuits allege inadequate warnings about serious gastrointestinal injuries. MDL-3094 coordinates those federal cases before Judge Karen Spencer Marston in Pennsylvania. Defendants dispute the allegations. NAION vision-loss claims proceed separately in MDL-3163.

Ozempic / GLP-1 Lawsuit update: September 2026

Rule 702 evidentiary hearing in progress September 14–18, 2026. The Eastern District of Pennsylvania's remote-access page states that Judge Marston is holding the hearing through September 18. This is an expert-evidence hearing, not a bellwether trial, and the court has not announced an outcome. NAION vision-loss claims are coordinated separately in MDL-3163.

The September 1, 2026 JPML report lists 4,022 pending actions in MDL-3094, compared with 3,928 on August 3. Its 4,056 total historical actions include cases no longer pending; neither figure is a count of people eligible for payment.

Official court records checked September 14, 2026.

Which drugs are included?

Filed cases involve GLP-1 receptor agonists from two manufacturers:

• Novo Nordisk: Ozempic and Rybelsus (semaglutide for type 2 diabetes), Wegovy (semaglutide for weight management), and Saxenda (liraglutide).
• Eli Lilly: Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide).

Both diabetes patients and weight-loss patients appear among filed cases. The medication involved, dose, duration of use, and documented injury all factor into claim review.

Who may qualify for the Ozempic lawsuit?

There is no automatic qualification rule. Claim review commonly considers:

• Documented use of a GLP-1 medication, supported by prescription and pharmacy records.
• A diagnosis such as gastroparesis, ileus, intestinal pseudo-obstruction, or bowel obstruction — often supported by a gastric emptying study, endoscopy, imaging, or hospitalization records.
• Injury timing relative to medication use, and whether other causes were ruled out or disputed.
• State filing deadlines and individual procedural facts.

Severe, medically documented injuries — particularly those involving hospitalization — have been the focus of filed cases.

What evidence can support an Ozempic lawsuit review?

A useful review usually starts with records that identify the GLP-1 medication, show when and how long it was used, document the diagnosed injury, and establish the timing between use, symptoms, and treatment. The evidence needed depends on the alleged injury and individual medical history; possessing a particular record does not guarantee that a claim qualifies.

• Medication proof: prescription records, pharmacy fills, product name, dose changes, and dates of use.
• Diagnosis proof: gastroenterology records, discharge summaries, and records identifying gastroparesis, ileus, bowel obstruction, or another alleged injury.
• Testing and treatment: gastric-emptying studies, imaging, endoscopy, emergency care, hospitalization, surgery, and follow-up treatment when relevant.
• Timeline: dates of medication use, first symptoms, diagnosis, treatment, and any decision to stop or change medication under medical supervision.
• Other medical context: records concerning alternative explanations, prior gastrointestinal history, and other medications may also matter.

The federal proceeding's current schedule and orders are available from the Eastern District of Pennsylvania's MDL-3094 page. Court coordination does not create a universal qualification checklist, and state filing deadlines still require individual review.

Case status snapshot

• Federal proceeding: MDL-3094; U.S. District Court, Eastern District of Pennsylvania
• Judge: Judge Karen Spencer Marston
• JPML transfer date: 2024-02-02
• Pending actions: 4,022 as of September 1, 2026
• Current phase: Rule 702 evidentiary hearing in progress September 14–18, 2026
• Settlement: The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.

Verified litigation updates

• JPML reports 4,022 pending actions on September 1, 2026, compared with 3,928 on August 3; 4,056 total historical actions are reported separately. Source
• An August 28 order rescheduled the Rule 702 evidentiary hearing to September 14–18, 2026. It is not a jury trial. Source
• The separate NAION vision-loss MDL-3163 has 216 pending actions as of September 1, compared with 200 on August 3. Source
• The public MDL orders checked September 14 contain no announced bellwether trial date or settlement program. Source

Current status

The Eastern District of Pennsylvania's remote-access page states that Judge Marston is holding the Rule 702 hearing from September 14 through September 18, 2026. This is an expert-evidence hearing, not a bellwether trial, and the court has not announced an outcome. NAION vision-loss claims are coordinated separately in MDL-3163.

The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.

Who may be affected

People who used a GLP-1 medication and then experienced severe, documented gastrointestinal injury — especially gastroparesis confirmed by a gastric emptying study, or a bowel obstruction or ileus requiring emergency care — are the focus of current filings. Family members may have wrongful-death-related questions where an injury contributed to a death; those claims involve additional state-specific rules.

Ozempic hearings and bellwether trials

The August 28 scheduling order sets the Rule 702 evidentiary hearing for September 14–18, 2026. It concerns expert admissibility and is not a bellwether jury trial. The order does not establish a completed hearing or a trial date. The earlier September 10 start is superseded.

Injuries alleged in filed cases

Gastroparesis — delayed gastric emptying that can cause persistent vomiting, malnutrition, and long-term complications. Ileus and bowel obstruction — intestinal blockage or paralysis that can require hospitalization or surgery. NAION — a sudden optic-nerve injury associated in some studies with semaglutide use, capable of causing permanent vision loss; NAION claims are consolidated in their own proceeding, MDL-3163 (216 pending actions as of September 1, 2026). Filed complaints also describe severe dehydration, aspiration events, and related complications.

Deadline considerations

GLP-1 claims follow state statutes of limitations, which commonly run two to three years from injury or discovery, depending on the state. Because GLP-1 injuries often develop during ongoing medication use, accrual and discovery-rule questions can be fact-intensive. State-specific pages below outline each state's general framework.

Sources and status notes

Counts use the September 1 JPML report and August 3 report. Court assignments and transfer dates use the JPML by-number report. Status was checked September 14, 2026 against public court records; these public indexes are not complete live dockets.

• An August 28 order rescheduled the Rule 702 evidentiary hearing to September 14–18, 2026. It is not a jury trial.
• The separate NAION vision-loss MDL-3163 has 216 pending actions as of September 1, compared with 200 on August 3.
• The public MDL orders checked September 14 contain no announced bellwether trial date or settlement program.

Defendants dispute the allegations. Hearing schedules do not establish an outcome, and pending-action counts do not establish settlement eligibility. State filing deadlines and settlement-program deadlines are different.

Where can I track the Ozempic / GLP-1 lawsuit?

Use the mass tort settlement tracker to compare public settlement posture, the deadline tracker for filing-window and key-date notes , and the MDL statistics tracker for federal case counts and court assignments.

What injuries does the Ozempic / GLP-1 lawsuit involve?

• Gastroparesis (delayed gastric emptying / stomach paralysis)
• Ileus and intestinal pseudo-obstruction
• Bowel obstruction
• Severe, persistent vomiting with complications
• NAION vision loss (separate proceeding — MDL-3163)

What evidence is needed for Ozempic / GLP-1 claims?

• Prescription and pharmacy records
• Records showing dates and duration of GLP-1 use
• Gastroenterology diagnosis records
• Gastric emptying study results
• Hospitalization and emergency records
• Endoscopy or imaging reports
• Treatment and medication-change records

How has the Ozempic / GLP-1 lawsuit progressed?

What is the Ozempic / GLP-1 settlement status?

The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.

What are the Ozempic / GLP-1 lawsuit filing deadlines?

Deadlines vary by state and may depend on diagnosis date, discovery date, exposure history, wrongful death issues, and other facts. A lawyer can evaluate how the relevant deadline rules may apply.

State-by-state guide links